Covid warning issued regarding side effects of new miracle pills: “Caution should be exercised” | Sciences | News

Last week, Pfizer announced an additional agreement with the UK government to provide an additional 2.5 million treatments of its Paxlovid, which is a home pill that patients with Covid can take. Meanwhile, US regulatory agencies also cleared Paxlovid and molnupiravir from Merck last week.

Both of these pills are expected to reduce the risk of hospitalization or death from COVID-19 in high-risk patients, although Pfizer’s pill appears to have much better results.

However, experts have warned about the side effects of these pills.

Molnupiravir by Merck is not approved for use in children because it may interfere with their bone growth.

Pregnant women are also discouraged from taking this pill because of the risk of birth defects.

Meanwhile, Pfizer’s Paxlovid pill is not recommended for patients with severe kidney or liver problems.

Experts have also warned that the new drug could be life threatening when taken with other drugs.

Pfizer treatment is a combination of two pills, the antiviral drug nirmatrelvir and one ritonavir tablet, taken over five days.

Pfizer said that Paxlovid tablets have been shown to be nearly 90 percent effective in preventing hospitalizations and death in high-risk patients.

READ MORE: AstraZeneca hailed for sparing UK from Omicron death crisis

This enzyme is specifically suppressed because it tends to break down many drugs, including nirmatrelvir.

This will help keep the antiviral properties of nirmatrelvir in the body at therapeutic levels for longer periods of time.

However, removing the liver causes other drugs to be stimulated to the point of becoming toxic.

The FDA said, “Therefore, caution should be taken when administering Paxlovid to patients with pre-existing liver disease, abnormal liver enzymes, or hepatitis. “

Comments are closed.